How are the stem cells introduced in my body?
Stem cells can be introduced into the body in several ways, and the route is chosen according to your condition.
At Stem Cell Mexico, the most common methods are direct injection into the affected area, guided by ultrasound for joints, tendons and ligaments or by fluoroscopy (live X-ray) for the spine, and intravenous (IV) infusion, which delivers cells into the bloodstream for systemic, whole-body effects. Other routes used in medicine and research, such as intrathecal delivery into the spinal fluid or intranasal application, are considered only for specific conditions after medical evaluation. Many plans combine routes, for example direct injection in the most affected joint plus an IV infusion. Most procedures are minimally invasive, and mild sedation is used when needed for comfort and precision.
The route matters because it determines where the cells go, how long they stay, how many reach the target and what risks are involved. This guide explains each method and how your doctor chooses among them.
Why the route matters
A review in Frontiers in Immunology (Caplan and colleagues, 2019) describes delivery as one of the main challenges in translating mesenchymal stromal cell (MSC) therapy into consistent clinical results. The same cells can behave very differently depending on how they are delivered:
- After IV infusion, many cells are temporarily trapped in the lungs within the first 24 to 48 hours, then redistributed to organs such as the spleen and liver before being cleared. Their effects are largely systemic and signal-based.
- After direct injection, cells remain longer in the target tissue and lose fewer numbers to the lungs.
- After intrathecal delivery, cells and their signals are placed in the fluid surrounding the brain and spinal cord.
Choosing the route is therefore part of the treatment design, not a technical detail. It also affects the dose your doctor prescribes, the setting in which the procedure is performed and the recovery you should plan for.
1. Direct injection with image guidance
How it works
The cells, often combined with platelet-rich plasma (PRP), are injected precisely into the injured or degenerated structure. The doctor uses:
- Ultrasound guidance for knees, hips, shoulders, elbows, ankles, wrists, tendons and ligaments. Ultrasound shows soft tissues in real time without radiation.
- Fluoroscopy guidance for the spine (discs, facet joints, sacroiliac joints), usually in a hospital setting, so needle placement can be confirmed precisely.
When it is used
Localized conditions such as osteoarthritis, tendinopathies, partial tears, degenerative disc disease and certain sports injuries.
What to expect
Mild sedation or local anesthesia is often used. The procedure usually takes less than an hour. Soreness and swelling for three to seven days are common.
Evidence
Direct intra-articular injection is the most studied route in osteoarthritis. A 2024 meta-analysis of 25 randomized trials in knee osteoarthritis found improvements in pain and function with MSC injections compared with control treatments and no difference in serious adverse events, although the evidence certainty was rated low. Randomized trials of intradiscal injection in degenerative disc disease have also shown reductions in pain and disability.
2. Intravenous (IV) infusion
How it works
Cells are suspended in a sterile solution and infused slowly through a vein in the arm, usually over 30 to 60 minutes, with monitoring of vital signs.
When it is used
Conditions with systemic or widespread inflammation or immune involvement, such as autoimmune conditions, some neurological conditions, frailty and certain wellness protocols. IV infusion may also complement local injections.
What to expect
The procedure is similar to receiving an IV medication. Some people feel tired or have a mild fever or headache for a day or two.
Considerations
Because many cells are temporarily filtered by the lungs, IV infusion is thought to work through circulating signals and immune modulation rather than large numbers of cells reaching a specific organ. Doses are usually higher than for local injections.
3. Intrathecal delivery
How it works
Cells are injected into the cerebrospinal fluid through a lumbar puncture in the lower back, similar to a spinal tap.
When it is used
Studied for neurological conditions, including spinal cord injury, multiple sclerosis and ALS.
Evidence
In 2024, Nature Communications published the CELLTOP phase 1 trial from Mayo Clinic, in which ten people with traumatic spinal cord injury received 100 million autologous fat-derived MSCs intrathecally. No serious adverse events were attributed to the treatment; headache and musculoskeletal pain were common but manageable, and several participants showed neurological improvement.
Considerations
Intrathecal procedures can cause headache, back pain and, rarely, infection or other complications, and they require specific expertise. They are considered only when the expected benefit justifies them.
4. Other routes
- Intranasal application: explored in research as a way to reach the brain or inner ear through nasal pathways.
- Intra-arterial delivery: brings cells closer to a target organ through an artery, used in some research protocols for stroke or heart disease, with risks such as small vessel blockages.
- Intramyocardial or transendocardial delivery: injection directly into heart muscle through a catheter, used in cardiology trials.
- Surgical implantation: used in some neurological trials, such as cell transplantation into the brain, requiring neurosurgery.
- Topical or subdermal application: used in skin, hair and aesthetic protocols.
A route to avoid outside regulated trials
Injections into the eye (intravitreal) outside of regulated clinical trials have caused severe vision loss in published reports, including a 2017 New England Journal of Medicine report of three patients with macular degeneration who became severely visually impaired after such injections. Eye procedures should only be performed by retina specialists within properly designed research protocols.
Combining routes: when it makes sense
Some patients have both a localized problem and a broader inflammatory or systemic component. For example, a person with severe knee osteoarthritis and widespread joint pain, or someone with degenerative disc disease and an autoimmune condition, may benefit from a plan that targets the most affected structure directly while using an IV infusion for systemic support. Combining routes can increase the total dose and cost, so it should be justified by your diagnosis rather than added by default. Your doctor should explain what each component is expected to contribute, and how results will be evaluated, so you can decide whether the combination is worthwhile for you.
How your doctor chooses the route
The decision considers:
- Where the problem is: a localized structure or a systemic process.
- The evidence for each route in your condition.
- Safety: your health status, blood thinners, bleeding risk and anatomy.
- Dose: local injections require fewer cells; systemic infusions require more.
- Combination: whether local and systemic approaches together are justified.
- Your preferences and comfort, including sedation options.
Sedation and comfort during the procedure
Many patients worry about needles, especially for spine or multiple-joint injections. For these procedures, mild sedation is often used so you are relaxed, comfortable and still, which also helps the specialist place the cells more precisely. You breathe on your own, and your vital signs are monitored throughout. Local anesthetic is used at injection sites. IV infusions usually do not require sedation. If you have had difficult experiences with procedures before, tell the team in advance so they can plan accordingly.
Preparing for your procedure
About seven days before treatment, you will usually pause anti-inflammatory painkillers, alcohol, tobacco and cannabis, and five days before, avoid dairy, fried foods and supplements such as omega 3, turmeric and ginger. Come fasting on the morning of the procedure and drink water as instructed. Share a full medication list, especially blood thinners.
After the procedure
- Direct injections: rest the day of treatment and the next day; light walking after about 10 days; gradual return to exercise with guidance; avoid heat or ice on the treated area for the first two days.
- IV infusions: most people resume light activities the next day.
- All routes: avoid alcohol for at least two weeks and anti-inflammatory supplements as instructed, and keep follow-up appointments.
Risks and limitations
Each route has specific risks: injection-site pain and swelling for direct injections; temporary fever or fatigue for IV infusions; headache or back pain for intrathecal procedures. Rare risks include infection, bleeding and allergic reactions. The best route and dose depend on the condition and are defined for each patient.
Questions to ask during your evaluation
- Which route do you recommend for my condition, and why?
- Will image guidance be used, and who performs the procedure?
- How many cells will be delivered by each route?
- What are the specific risks of this route for me?
- What recovery should I plan for?
Bottom line
Stem cells are introduced most commonly by image-guided direct injection or IV infusion, and in selected cases by other routes. The route is chosen to match your condition, evidence and safety profile. A medical evaluation can help determine which delivery method is appropriate for your condition, goals and medical history.
References
- Caplan H, Olson SD, Cox CS Jr et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Frontiers in Immunology, 2019 (opens in a new tab)
- Bydon M et al. Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: phase I trial. Nature Communications, 2024 (opens in a new tab)
- Tabet CG et al. Advanced therapy with mesenchymal stromal cells for knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Translation, 2024 (opens in a new tab)
- Kuriyan AE et al. Vision loss after intravitreal injection of autologous stem cells for AMD. The New England Journal of Medicine, 2017 (opens in a new tab)
